RTOG-85-01-LONG-TERM

Regimen

Experimental
cisplatin/5-FU + 50 Gy RT (combined modality)
Control
64 Gy RT alone

Population

Locally advanced T1-3 N0-1 M0 thoracic esophageal carcinoma (squamous or adenocarcinoma), long-term follow-up

Key finding

5-year OS 26% (CRT) vs 0% (RT-alone); 8-year OS 22% CRT vs 0% RT-alone. Durable benefit of adding chemotherapy to RT.

Source: PMID 10235156

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.53)